Featured PodcastPodcast Highlights

New Developments in Tetracycline-Class Antibiotics

By December 21, 2020March 18th, 2021No Comments

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

New Developments in Tetracycline-class Antibiotics

Dr. Christopher Bunick & Dr. Adam Friedman

 

Tetracycline antibiotics are like the Snickers of dermatology. Instead of “Hungry? Grab a Snickers,” “Acne? Grab a tetracycline…” for months even though this goes against clinical guidelines and concerns regarding antimicrobial resistance (woof, thats a mouthful for a slogan). Like a Snickers, they fulfill a need, they’re good for a whole lot, but too much, not so good. We have seen some evolution in maximizing the clinical benefits of our therapeutic Snickers, such as subantimicrobial dosing, but more innovation is needed to get the most anti-inflammatory bang for our buck. Enter the concept of narrow spectrum antibiotics and sarecycline.

 Join host Dr. Adam Friedman on an investigative journey detailing how antibiotic structure and function can meet to yield novel properties with Dr. Chris Bunick, Associate Professor of Dermatology at Yale School of Medicine and captain of crystallography and cryo-electron microscopy. Hear first hand how a simple idea morphed into a groundbreaking program. Complete your understanding of how antibiotics can be anti-inflammatory. Love the new narrow spectrum lexicon (or try at least).

Listen Now
This enduring activity is supported by an independent medical education grant provided by Almirall, LLC.
Learning Objectives
Upon completion of this podcast, learners should be able to:
  • Summarize the mechanism of action of tetracycline antibiotics and their role in acne
  • Define narrow spectrum antibiotic, and understand the clinical translation.

Disclosures

 

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
Christopher Bunick, MD, PhD – Grant/Research: Almirall, Consultant: Almirall, Speakers’ Bureau: Almirall

You May Also Like

Wondering about Words: Evidence Based Framing for Improving Treatment Adherence

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Spotify Hosts: Dr. Adam Friedman and Dr. Steven Feldman Actions speak louder than words…so long as the words inspire, encourage, engage, etc. the actions. This…

Prevention is the Best Medicine: ADing up the Data

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Spotify Dr. Candrice Heath, Dr. Jonathan O’B. Hourihane & Dr. Adam Friedman Atopic Dermatitis (AD) is the second most common chronic inflammatory (coming for you…

See Ya ciAREs: A Review of Mitigation and Management Strategies for Immunotherapy Associated Skin Scares

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Spotify Dr. Beth McLellan & Adam Friedman, MD, FAAD Mo’ targeted therapies, mo’skin problems. Some may say, “Bring on the problems” – but why should they…

Leave a Reply